![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/2119136921/2089647169/gr1.gif)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
![First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-022-01737-2/MediaObjects/41416_2022_1737_Fig1_HTML.png)
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
![Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study | Journal of Clinical Oncology Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.2009.27.7723/asset/images/zlj9991001420001.jpeg)
Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study | Journal of Clinical Oncology
![PPT - Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC) PowerPoint Presentation - ID:3905318 PPT - Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC) PowerPoint Presentation - ID:3905318](https://image2.slideserve.com/3905318/xeloda-is-an-ideal-combination-partner-for-cytotoxic-and-biological-agents-l.jpg)
PPT - Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC) PowerPoint Presentation - ID:3905318
![Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram](https://www.researchgate.net/publication/261521879/figure/fig2/AS:327843612512263@1455175416566/Effects-of-bevacizumab-Avastin-R-and-capecitabine-Xeloda-R-on-the-expression-of.png)
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
![4. Cancer colorectal métastatique | SNFGE.org - Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive 4. Cancer colorectal métastatique | SNFGE.org - Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive](https://www.snfge.org/sites/www.snfge.org/files/SNFGE/TNCD/tncd_chap-04_figure-01_2023.png)
4. Cancer colorectal métastatique | SNFGE.org - Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive
![Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model](https://www.spandidos-publications.com/article_images/or/36/2/OR-36-02-0626-g01.jpg)
Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model
![Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram](https://www.researchgate.net/profile/Xiaozhou-Mou/publication/261521879/figure/fig3/AS:327843612512264@1455175416629/Effects-of-bevacizumab-Avastin-R-and-capecitabine-Xeloda-R-on-the-expression-of_Q320.jpg)
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
![Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments](https://www.mdpi.com/diseases/diseases-11-00148/article_deploy/html/images/diseases-11-00148-g001.png)
Diseases | Free Full-Text | Progress and Perspectives in Colon Cancer Pathology, Diagnosis, and Treatments
![Avastin ® : setting the standard in treatment for metastatic colorectal cancer (CRC) Fairooz Kabbinavar David Geffen School of Medicine at UCLA Los Angeles, - ppt download Avastin ® : setting the standard in treatment for metastatic colorectal cancer (CRC) Fairooz Kabbinavar David Geffen School of Medicine at UCLA Los Angeles, - ppt download](https://slideplayer.com/6459165/22/images/slide_1.jpg)
Avastin ® : setting the standard in treatment for metastatic colorectal cancer (CRC) Fairooz Kabbinavar David Geffen School of Medicine at UCLA Los Angeles, - ppt download
![Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/6534dfdf-78f1-455e-a2de-fe35e8439def/gr3.jpg)
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial - The Lancet Oncology
![Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram](https://www.researchgate.net/profile/Xiaozhou-Mou/publication/261521879/figure/fig2/AS:327843612512263@1455175416566/Effects-of-bevacizumab-Avastin-R-and-capecitabine-Xeloda-R-on-the-expression-of_Q320.jpg)
Effects of bevacizumab (Avastin ® ) and capecitabine (Xeloda ® ) on the... | Download Scientific Diagram
![PPT - Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC) PowerPoint Presentation - ID:3905318 PPT - Xeloda: simplifying the complexity of treatment for metastatic colorectal cancer (MCRC) PowerPoint Presentation - ID:3905318](https://image2.slideserve.com/3905318/xeloda-simplifying-the-complexity-of-treatment-for-metastatic-colorectal-cancer-mcrc-l.jpg)